Literature DB >> 17301845

Darwinian medicine: a case for cancer.

Mel Greaves1.   

Abstract

Epidemiological, genetic and molecular biological studies have collectively provided us with a rich source of data that underpins our current understanding of the aetiology and molecular pathogenesis of cancer. But this perspective focuses on proximate mechanisms, and does not provide an adequate explanation for the prevalence of tumours and cancer in animal species or what seems to be the striking vulnerability of Homo sapiens. The central precept of Darwinian medicine is that vulnerability to cancer, and other major diseases, arises at least in part as a consequence of the 'design' limitations, compromises and trade-offs that characterize evolutionary processes.

Entities:  

Mesh:

Year:  2007        PMID: 17301845     DOI: 10.1038/nrc2071

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  59 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 2.  Mutations, Cancer and the Telomere Length Paradox.

Authors:  Abraham Aviv; James J Anderson; Jerry W Shay
Journal:  Trends Cancer       Date:  2017-03-27

3.  Does everyone develop covert cancer?

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

4.  Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data.

Authors:  Yong Tao; Jue Ruan; Shiou-Hwei Yeh; Xuemei Lu; Yu Wang; Weiwei Zhai; Jun Cai; Shaoping Ling; Qiang Gong; Zecheng Chong; Zhengzhong Qu; Qianqian Li; Jiang Liu; Jin Yang; Caihong Zheng; Changqing Zeng; Hurng-Yi Wang; Jing Zhang; Sheng-Han Wang; Lingtong Hao; Lili Dong; Wenjie Li; Min Sun; Wei Zou; Caixia Yu; Chaohua Li; Guojing Liu; Lan Jiang; Jin Xu; Huanwei Huang; Chunyan Li; Shuangli Mi; Bing Zhang; Baoxian Chen; Wenming Zhao; Songnian Hu; Shi-Mei Zhuang; Yang Shen; Suhua Shi; Christopher Brown; Kevin P White; Ding-Shinn Chen; Pei-Jer Chen; Chung-I Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

Review 5.  Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations.

Authors:  Andriy Marusyk; James DeGregori
Journal:  Biochim Biophys Acta       Date:  2007-10-12

6.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.

Authors:  Steffen E Eikenberry; John D Nagy; Yang Kuang
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

7.  Tumor suppressors: enhancers or suppressors of regeneration?

Authors:  Jason H Pomerantz; Helen M Blau
Journal:  Development       Date:  2013-06       Impact factor: 6.868

Review 8.  Was skin cancer a selective force for black pigmentation in early hominin evolution?

Authors:  Mel Greaves
Journal:  Proc Biol Sci       Date:  2014-02-26       Impact factor: 5.349

9.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.

Authors:  Kenneth J Pienta; Natalie McGregor; Robert Axelrod; David E Axelrod
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

10.  Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.

Authors:  Zhenbin Chen; Jinong Feng; Carolyn H Buzin; Qiang Liu; Lawrence Weiss; Kemp Kernstine; George Somlo; Steve S Sommer
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.